Publication:
Stereotactic radiotherapy in the treatment of lung cancer – current prospective

Simple item page
dc.contributor.authorPoparić-Banđur, Bojana (59527749300)
dc.contributor.authorMilošević-Maračić, Brankica (58313802300)
dc.contributor.authorStepanović, Aleksandar (57201691091)
dc.contributor.authorNikitović, Marina (6602665617)
dc.contributor.authorArsenijević, Tatjana (6508074168)
dc.date.accessioned2025-06-12T11:40:21Z
dc.date.available2025-06-12T11:40:21Z
dc.date.issued2024
dc.description.abstractStereotactic body radiotherapy (SBRT) is the standard treatment for early-stage inoperable non-small cell lung cancer. SBRT achieves a high local control rate (74–100%), preserves the quality of life, and the treatment is of low-toxicity. Different fractionation regimens are used, depending on the localization and size of the tumor, the proximity of the organs at risk, and the general condition of the patient. The radiobiology behind SBRT is largely unknown, precisely defined radiation doses and the number of fractions are still a matter of debate. Numerous studies are ongoing regarding the standardization of SBRT in lung cancer treatment. © 2024, Serbia Medical Society. All rights reserved.
dc.identifier.urihttps://doi.org/10.2298/SARH240716070P
dc.identifier.urihttps://www.scopus.com/inward/record.uri?eid=2-s2.0-85215947019&doi=10.2298%2fSARH240716070P&partnerID=40&md5=b30ef5170691ce489203891b9790782e
dc.identifier.urihttps://remedy.med.bg.ac.rs/handle/123456789/870
dc.subjectearly stage
dc.subjectlung cancer
dc.subjectstereotactic body radiotherapy
dc.titleStereotactic radiotherapy in the treatment of lung cancer – current prospective
dspace.entity.typePublication

Files

Collections

Publikacije / Publications